DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) PATIENTS: RESPONSE RATE IMPACTS ON PFS

Autor: EQ Crusoé, JSLRD Santos, JAD Santos, HHM Santos, AS Santos, LF Lucas, AM Almeida, VT Hungria, MA Salvino, MGB Arruda

Publikováno v: Hematology, Transfusion and Cell Therapy. 44:S267

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::612632e643361f390a2788dbc6b0a7d1
https://doi.org/10.1016/j.htct.2022.09.451

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.

Autor: Hájek R; University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, 703 00, Czech Republic., Minařík J; Palacky University & University Hospital Olomouc, Olomouc, 771 47, Czech Republic., Straub J; General Teaching Hospital, Prague, 128 08, Czech Republic., Pour L; University Hospital, Brno, 625 00, Czech Republic., Jungova A; Faculty Hospital Pilsen, Pilsen, 301 00, Czech Republic., Berdeja JG; Sarah Cannon Research Institute, Nashville, TN 37203, USA., Boccadoro M; University of Torino, Torino, 10124, Italy., Brozova L; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Spencer A; Alfred Health-Monash University, Melbourne, 3004, Australia., van Rhee F; University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA., Vela-Ojeda J; UMAE Especialidades Centro Medico La Raza IMSS, Ciudad de México, 02990, Mexico., Thompson MA; Advocate Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI 53227, USA., Abonour R; Indiana University School of Medicine, Indianapolis, IN 46202, USA., Chari A; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Cook G; Leeds Teaching Hospital, Leeds, LS1 3EX, UK., Costello CL; Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA., Davies FE; Perlmutter Cancer Center, NYU Langone, New York, NY 10016, USA., Hungria VT; Clinica São Germano & Santa Casa Medical School, São Paulo, 04537-081, Brazil., Lee HC; M.D. Anderson Cancer Center, Houston, TX 77030, USA., Leleu X; Pôle Régional de Cancérologie, CHU de Poitiers, Poitiers, 86000, France., Puig N; Department of Hematology, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC (CB16/12/00233), Salamanca, 37007, Spain., Rifkin RM; Rocky Mountain Cancer Centers US Oncology Research, Denver, CO 80218, USA., Terpos E; National & Kapodistrian University of Athens, School of Medicine, Athens, 115 27, Greece., Usmani SZ; Levine Cancer Institute, Charlotte, NC 115 27, USA., Weisel KC; University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany., Zonder JA; Barbara Ann Karmanos Cancer Institute / Wayne State University School of Medicine, Detroit, MI 48201, USA., Bařinová M; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Kuhn M; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Šilar J; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Čápková L; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Galvez K; Hospital Pablo Tobón Uribe, Medellin, 11001, Colombia., Lu J; Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Beijing, 100044, China., Elliott J; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Stull DM; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Ren K; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Maisnar V; Charles University Hospital & Faculty of Medicine, Hradec Králové, 121 08, Czech Republic.

Publikováno v: Future oncology (London, England) [Future Oncol] 2021 Jul; Vol. 17 (19), pp. 2499-2512. Date of Electronic Publication: 2021 Mar 26.

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.

Autor: San-Miguel JF; Clínica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain. Electronic address: sanmiguel@unav.es., Hungria VT; Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil., Yoon SS; Seoul National University Hospital, Seoul, South Korea., Beksac M; Ankara University School of Medicine, Ankara, Turkey., Dimopoulos MA; National and Kapodistrian University of Athens, Athens, Greece., Elghandour A; Alexandria University, Alexandria, Egypt., Jedrzejczak WW; Medical University of Warsaw, Warsaw, Poland., Günther A; University of Kiel, Kiel, Germany., Nakorn TN; King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand., Siritanaratkul N; Siriraj Hospital, Bangkok, Thailand., Schlossman RL; Dana-Farber Cancer Institute, Boston, MA, USA., Hou J; Shanghai Changzheng Hospital, Shanghai, China., Moreau P; University Hospital of Nantes, Nantes, France., Lonial S; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Lee JH; Gachon University Gil Medical Center, Incheon, South Korea., Einsele H; University Hospital Würzburg, Würzburg, Germany., Sopala M; Novartis Pharma AG, Basel, Switzerland., Bengoudifa BR; Novartis Pharma AG, Basel, Switzerland., Binlich F; Novartis Pharma SAS, Rueil-Malmaison, France., Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2016 Nov; Vol. 3 (11), pp. e506-e515. Date of Electronic Publication: 2016 Oct 14.

Bilateral breast plasmacytoma: a clinical case report.

Autor: Fischer TR; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil. Electronic address: thaisfischer@hotmail.com., Higashi F; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil., Crusoe Ede Q; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil., Hungria VT; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil.

Publikováno v: Revista brasileira de hematologia e hemoterapia [Rev Bras Hematol Hemoter] 2016 Apr-Jun; Vol. 38 (2), pp. 166-9. Date of Electronic Publication: 2016 Mar 25.

Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible.

Autor: Hungria VT; Department of Hematology and Oncology, Santa Casa de São Paulo Medical School, Rua Marquês de Itu, 579-3° andar, CEP 01223-001, São Paulo, Brazil. hungria@dialdata.com.br., Crusoé EQ; Department of Hematology and Oncology, Santa Casa de São Paulo Medical School, Rua Marquês de Itu, 579-3° andar, CEP 01223-001, São Paulo, Brazil., Maiolino A; Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Bittencourt R; Universidade Federal de Porto Alegre, Porto Alegre, Brazil., Fantl D; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Maciel JF; Liga Norte-Riograndense Contra o Câncer, Natal, Brazil., Pessoa de Magalhaes RJ; Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Almeida MS; Department of Hematology and Oncology, Santa Casa de São Paulo Medical School, Rua Marquês de Itu, 579-3° andar, CEP 01223-001, São Paulo, Brazil., Cury P; Department of Hematology and Oncology, Santa Casa de São Paulo Medical School, Rua Marquês de Itu, 579-3° andar, CEP 01223-001, São Paulo, Brazil., Hisgashi F; Department of Hematology and Oncology, Santa Casa de São Paulo Medical School, Rua Marquês de Itu, 579-3° andar, CEP 01223-001, São Paulo, Brazil., Peres AL; Department of Hematology and Oncology, Santa Casa de São Paulo Medical School, Rua Marquês de Itu, 579-3° andar, CEP 01223-001, São Paulo, Brazil., Chiattone CS; Department of Hematology and Oncology, Santa Casa de São Paulo Medical School, Rua Marquês de Itu, 579-3° andar, CEP 01223-001, São Paulo, Brazil.

Publikováno v: Annals of hematology [Ann Hematol] 2016 Jan; Vol. 95 (2), pp. 271-8. Date of Electronic Publication: 2015 Oct 30.